- Samsung Biologics launches S-HiCon platform to optimize high-concentration biopharmaceutical formulations.
- The platform addresses pH stability, viscosity, and protein aggregation challenges in drug development.
Samsung Biologics has launched a new high-concentration formulation platform, S-HiCon, designed to support the development of high-dose biopharmaceuticals. The platform is aimed at improving formulation stability, reducing viscosity, and ensuring the efficacy of drugs with high concentration requirements.
The platform uses a range of optimisation techniques, including pH, buffer species, and excipients, to help identify favourable candidates early in development. Samsung Biologics has also introduced a “Concentration Gate Check” process, which tests formulation feasibility in the initial stages to minimise risks associated with high-concentration drug development.
This launch marks another step in Samsung Biologics’ ongoing efforts to provide advanced contract manufacturing solutions to its clients. “Our new platform will enable us to provide innovative solutions for clients requiring low to ultra-high concentration formulation to develop advanced therapeutics,” said Brian Hosung Min, Executive Vice President and Head of CDO Development at Samsung Biologics.
The S-HiCon platform integrates analytical capabilities to address critical issues such as protein aggregation and viscosity. Samsung Biologics reports that it has achieved over 200 mg/mL for liquid formulations, with improved stability. The company’s offering is expected to help clients meet evolving needs in biologics development and contract manufacturing.
Overview of outsourcing trends 
